TICKERNERD
Menu
CORTCORTHealthcare · Biotechnology

CORT Stock Forecast: Corcept Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 27 Oct 2026
$88
+0.53% on the day

The 5 Wall Street analysts covering Corcept Therapeutics, Inc. hold a median 12-month price target of $164 — +87.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 26 Oct 2026 — in the upper half.

Market cap
$9.3B
Ticker Nerd rank
68/ 100
Median analyst target
$164
Analysts covering
5
Revenue$256.1M+31.7% y/y
Operating income$41.3M
Net income$43.0M
Free cash flow$31.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−24.8%
1M
−24.6%
YTD
+151.7%
1Y
+20.7%
From 52W high
−29.1%
From 52W low
+172.4%
$32
$124
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CORT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Corcept Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 26 Oct 2026
68/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
84
Revisions
69
Momentum
67
Volatility
63
Growth
48
Accruals
42
Issuance
42
Size
16

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (42): The company has been issuing shares or taking on financing, diluting existing holders.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CORT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CORT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150Jan 26Apr 26Jul 26Oct 26CORTHigh $165Median $164Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy0 Hold1 Sell
Low $50Median $164High $165

The green dot is the last close — the median target sits +87.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
18 Sept 2026HC Wainwright & Co.ReiteratesBuy$165
30 July 2026Canaccord GenuityMaintainsBuy—
30 July 2026Canaccord GenuityMaintainsBuy$150 → $161
30 July 2026HC Wainwright & Co.MaintainsBuy—
30 July 2026HC Wainwright & Co.MaintainsBuy$95 → $165
30 July 2026Piper SandlerReiteratesOverweight$88 → $165
30 July 2026Piper SandlerReiteratesOverweight—
29 July 2026Canaccord GenuityMaintainsBuy$135 → $150
29 July 2026Canaccord GenuityMaintainsBuy—
27 July 2026Wolfe ResearchDowngradeUnderperform—
27 July 2026Wolfe ResearchDowngradeUnderperform$50
28 May 2026Canaccord GenuityMaintainsBuy—
28 May 2026Canaccord GenuityMaintainsBuy$110 → $135
28 May 2026HC Wainwright & Co.MaintainsBuy—
28 May 2026HC Wainwright & Co.MaintainsBuy$75 → $95
13 May 2026UBSUpgradeBuy—
4 May 2026HC Wainwright & Co.MaintainsBuy—
1 May 2026Piper SandlerMaintainsOverweight—
26 Mar 2026Canaccord GenuityMaintainsBuy—
26 Mar 2026Wolfe ResearchUpgradePeer Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CORT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

Performance

CORT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 27 Oct 2026, Corcept Therapeutics, Inc. returned +20.7% against +12.9% for the S&P 500, dividends included.

CORT vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150Jan 26Apr 26Jul 26Oct 26CORTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CORT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+280.8%
Analysts raising
1
Analysts cutting
0
Fundamentals

Corcept Therapeutics, Inc. (CORT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
190.8×

Cheaper than 3% of US stocks

Price / sales
11.2×

Cheaper than 12% of US stocks

Price / book
13.1×

Cheaper than 7% of US stocks

EV / EBITDA
1111.2×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
31.7%

Higher than 79% of US stocks

Earnings growth (YoY)
22.3%

Higher than 61% of US stocks

Gross margin
98.4%

Higher than 99% of US stocks

Operating margin
16.1%

Higher than 74% of US stocks

Net margin
6.6%

Higher than 64% of US stocks

Returns & dividend
Return on equity
8.2%

Higher than 59% of US stocks

Return on assets
0.5%

Higher than 46% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Corcept Therapeutics, Inc. (CORT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Corcept Therapeutics, Inc. has a market value of $9.3B and an enterprise value of $9.0B.

  • Revenue in the twelve months to 30 June 2026: $830.8M. The latest quarter grew 31.7% year on year.

  • Net income over the same four quarters: $55.2M, a 6.6% net margin.

  • Diluted earnings per share, trailing twelve months: $0.42.

  • Free cash flow in the twelve months to 30 June 2026: $106.9M.

  • Shares outstanding: 107.9M.

  • Trailing P/E: 190.8×; forward P/E: 19.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Corcept Therapeutics, Inc. employs 730 people — $1.1M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 27 Oct 2026

Data provided by Twelve Data

Peers

CORT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CORTCorcept Therapeutics, Inc.$9.3B68
KRYSKrystal Biotech, Inc.$9.3B74
PCVXVaxcyte, Inc.$9.4B55
CAICaris Life Sciences, Inc.$9.2B43
KYMRKymera Therapeutics, Inc.$9.5B82
TWSTTwist Bioscience Corp.$9.6B70
PTGXProtagonist Therapeutics, Inc.$9.0B98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Corcept Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CORT news & analysis

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Business Wire · 27 Oct 2026neutral

Corcept Therapeutics announced it will report third-quarter financial results and provide a corporate update on November 3, 2026. It will also host a conference call at 5:00 p.m. Eastern Time that day, with advance registration required.

Why it matters — CORT watchers can note the date and time for the company’s results, update, and conference call.

Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer

Business Wire · 26 Oct 2026positive

Corcept reported positive results from Part A of its Phase 2 BELLA trial, which evaluated Lifyorli combined with nab-paclitaxel and bevacizumab in 95 patients with platinum-resistant ovarian cancer.

Why it matters — The trial results provide an update on Corcept’s evaluation of Lifyorli in an oncology setting.

2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes

Business Wire · 20 Oct 2026positive

Corcept announced that the ADA and EASD published their 2026 consensus report on the Management of Type 2 Diabetes. The headline says the report recommends screening for hypercortisolism in patients with difficult-to-control type 2 diabetes.

Why it matters — The recommendation is relevant to CORT because the company focuses on medications that modulate cortisol’s effects.

Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?

Zacks Investment Research · 19 Oct 2026positive

Corcept is relying on its newly approved drug, Lifyorli, while potential future approvals and clinical studies could expand its business beyond Korlym.

Why it matters — CORT watchers may track whether Lifyorli and the broader development pipeline diversify revenue beyond Korlym.

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains

Zacks Investment Research · 16 Oct 2026positive

Zacks Investment Research names CORT among five non-tech Nasdaq stocks it says are riding strong growth trends and rising earnings estimates, highlighting them for potential Q4 gains.

Why it matters — The item places Corcept among stocks associated with strong growth trends and rising earnings estimates.

FAQ

Frequently asked questions about CORT stock

What is the CORT stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Corcept Therapeutics, Inc. have a median 12-month price target of $164, with estimates ranging from $50 to $165. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CORT stock a buy right now?

Of the 5 analysts covering Corcept Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Corcept Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 26 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CORT?

As at 26 Oct 2026, Corcept Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will CORT stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +87.2% from the last close, and Ticker Nerd's factor model ranks Corcept Therapeutics, Inc. 68 out of 100 as at 26 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CORT stock forecast for 2030?

No analyst covering Corcept Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CORT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $165 over the next 12 months.

How has CORT stock performed over the past year?

Corcept Therapeutics, Inc. returned +20.7% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Corcept Therapeutics, Inc. do?

Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders.

What is the latest news on CORT?

The most recent item we track (Business Wire, 27 Oct 2026): "Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call". Corcept Therapeutics announced it will report third-quarter financial results and provide a corporate update on November 3, 2026. It will also host a conference call at 5:00 p.m. Eastern Time that day, with advance registration required.

Company

About Corcept Therapeutics, Inc.

Corcept Therapeutics Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines that modulate cortisol activity to address serious endocrine, oncologic, metabolic, and neurologic disorders. Its commercial portfolio is centered on Korlym, an oral therapy used for adults with endogenous Cushing’s syndrome and related hypercortisolism. The company also advances a pipeline of selective cortisol modulators across multiple therapeutic areas, including relacorilant for Cushing’s syndrome and certain cancers, Lifyorli for oncology, and other investigational programs in metabolic disease and amyotrophic lateral sclerosis. Corcept Therapeutics serves the specialized rare-disease and specialty-pharmaceutical markets, where its products and research are aimed at conditions with limited treatment options. The company is headquartered in Redwood City, California.

CEO Dr. Joseph K. Belanoff M.D. · 730 employees · United States · https://www.corcept.com